Brian D Gonzalez1, Heather S L Jim1, Kristine A Donovan1, Brent J Small1, Steve K Sutton1, Jong Park1, Hui-Yi Lin1, Philippe E Spiess1, Mayer N Fishman1, Paul B Jacobsen2. 1. Health Outcomes and Behavior Program, Moffitt Cancer Center, Tampa, Florida; Supportive Care Medicine, Moffitt Cancer Center, Tampa, Florida; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida; Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, Florida; School of Aging Studies, University of South Florida, Tampa, Florida. 2. Health Outcomes and Behavior Program, Moffitt Cancer Center, Tampa, Florida; Supportive Care Medicine, Moffitt Cancer Center, Tampa, Florida; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida; Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, Florida; School of Aging Studies, University of South Florida, Tampa, Florida. Electronic address: Paul.Jacobsen@Moffitt.org.
Abstract
PURPOSE: Many men receiving androgen deprivation therapy for prostate cancer experience hot flashes. This study aimed to describe the course of hot flash interference with time in androgen deprivation therapy recipients relative to matched prostate cancer and cancer-free controls from before the start of androgen deprivation therapy to 12 months later. We also examined demographic, clinical and genetic predictors of the impact of androgen deprivation therapy on hot flash interference. MATERIALS AND METHODS: Three groups were examined, including 60 patients with prostate cancer recruited before or within 21 days of starting androgen deprivation therapy, 83 age and education matched patients with prostate cancer treated with prostatectomy only, and 86 age and education matched men with no history of cancer. Participants provided blood samples and completed the Hot Flash Related Daily Interference Scale at baseline as well as 6 and 12 months later. RESULTS: Androgen deprivation therapy recipients reported increasing hot flash interference with time relative to controls (p <0.001). Group differences were evident at 6 and 12 months (all p <0.001) with androgen deprivation therapy recipients reporting greater hot flash interference than controls. Several genetic polymorphisms were found to predict greater increases in hot flash interference (all p <0.01), including polymorphisms on genes associated with vasoconstriction, immune function, neurotransmission and circadian rhythms. Androgen deprivation therapy recipients who were younger and had a lower body mass index at baseline also showed greater increases in hot flash interference with time (all p ≤0.01). CONCLUSIONS: This study, which is to our knowledge the first to prospectively examine hot flash interference in androgen deprivation therapy recipients, reveals that those with certain genetic polymorphisms, younger age and lower body mass index had greater increases in hot flash interference with time relative to controls.
PURPOSE: Many men receiving androgen deprivation therapy for prostate cancer experience hot flashes. This study aimed to describe the course of hot flash interference with time in androgen deprivation therapy recipients relative to matched prostate cancer and cancer-free controls from before the start of androgen deprivation therapy to 12 months later. We also examined demographic, clinical and genetic predictors of the impact of androgen deprivation therapy on hot flash interference. MATERIALS AND METHODS: Three groups were examined, including 60 patients with prostate cancer recruited before or within 21 days of starting androgen deprivation therapy, 83 age and education matched patients with prostate cancer treated with prostatectomy only, and 86 age and education matched men with no history of cancer. Participants provided blood samples and completed the Hot Flash Related Daily Interference Scale at baseline as well as 6 and 12 months later. RESULTS: Androgen deprivation therapy recipients reported increasing hot flash interference with time relative to controls (p <0.001). Group differences were evident at 6 and 12 months (all p <0.001) with androgen deprivation therapy recipients reporting greater hot flash interference than controls. Several genetic polymorphisms were found to predict greater increases in hot flash interference (all p <0.01), including polymorphisms on genes associated with vasoconstriction, immune function, neurotransmission and circadian rhythms. Androgen deprivation therapy recipients who were younger and had a lower body mass index at baseline also showed greater increases in hot flash interference with time (all p ≤0.01). CONCLUSIONS: This study, which is to our knowledge the first to prospectively examine hot flash interference in androgen deprivation therapy recipients, reveals that those with certain genetic polymorphisms, younger age and lower body mass index had greater increases in hot flash interference with time relative to controls.
Authors: Matthew P Goetz; James M Rae; Vera J Suman; Stephanie L Safgren; Matthew M Ames; Daniel W Visscher; Carol Reynolds; Fergus J Couch; Wilma L Lingle; David A Flockhart; Zeruesenay Desta; Edith A Perez; James N Ingle Journal: J Clin Oncol Date: 2005-12-20 Impact factor: 44.544
Authors: Sheila N Garland; Josée Savard; Sarah L Eisel; Richard J Wassersug; Nicholas J Rockwood; John Thoms; Heather S L Jim; Brian D Gonzalez Journal: Cancer Date: 2021-08-19 Impact factor: 6.860
Authors: Ashley M Nelson; Brian D Gonzalez; Heather S L Jim; Julie M Cessna; Steven K Sutton; Brent J Small; Mayer N Fishman; Babu Zachariah; Paul B Jacobsen Journal: Support Care Cancer Date: 2016-05-03 Impact factor: 3.603
Authors: Brian D Gonzalez; Brent J Small; Mallory G Cases; Noelle L Williams; Mayer N Fishman; Paul B Jacobsen; Heather S L Jim Journal: Cancer Date: 2017-10-26 Impact factor: 6.860
Authors: Pawel J Wiechno; Grazyna M Poniatowska; Wojciech Michalski; Jakub Kucharz; Malgorzata Sadowska; Joanna Jonska-Gmyrek; Karol Nietupski; Joanna Rzymowska; Tomasz Demkow Journal: Med Oncol Date: 2017-06-01 Impact factor: 3.064